« Return to News | CROs/Service Providers

CRO Solutions launches VxP Pharma

Wednesday, July 24, 2013 10:00 AM

CRO Solutions has launched VxP Pharma, a wholly-owned subsidiary. VxP Pharma offers the combined services of the independently owned and operated "niche" CROs of its parent company. VxP Pharma will offer pharmaceutical development services and technical support from discovery through phase IIb.

The majority of VxP Pharma's labs are in the U.S., although it also has facilities in Europe and Asia. All sites have been fully audited by CRO Solutions and VxP Pharma, as well as by global pharmaceutical and biotechnology clients. Most sites also have been audited by the FDA and other  regulatory agencies.

"Pharmaceutical and biotech research scientists throughout the industry tell us that they prefer to work with smaller, focused CROs, rather than with the huge multinational 'one-size-fits-all' CROs,” said Raymond E Peck, VxP Pharma chief executive officer. “For these people, VxP Pharma fits because we offer a single point of contact. Because VxP consists of smaller, independently owned and operated facilities that focus only on one area of drug development, our clients get all the advantages of working directly with a specialist ‘niche’ CRO."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.